Publication date: Jul 10, 2025
An undetectable ctDNA result does not definitively mean the absence of diseaseit may reflect assay sensitivity, low tumor burden, or biological factors such as tumor shedding. For example, one institution collects ctDNA for most patients with stage IIB or higher melanoma, using platforms such as Nateras genomic assay to monitor tumor dynamics. However, this use remains in the research realm, with the data helping inform trends rather than driving clinical decisions. One panelist notes limited but thoughtful use in clinical scenarios where imaging is inconclusive or biopsy is impractical. In the final segment of this discussion, the panel explores the evolving role of ctDNA in managing metastatic melanoma. As the field advances, ctDNA could become a valuable biomarker, but for now, it remains largely investigational.
| Concepts | Keywords |
|---|---|
| Ctdna | Assay |
| Driving | Clinical |
| Fda | Ctdna |
| Impractical | Diagnosis |
| Stage | Final |
| Integrate | |
| Management | |
| Melanoma | |
| Metastatic | |
| Panel | |
| Panelist | |
| Remains | |
| Segment | |
| Testing | |
| Tumor |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Melanoma |
| pathway | KEGG | Melanoma |
| disease | MESH | tumor |